An observational study in Hypertension and Obesity, sponsored by Boehringer Ingelheim. Completed at 2,389 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-08.
Sponsored by Boehringer Ingelheim · Observational
This observational non-interventional study will assess (under conditions of clinical practice in daily routine) the antihypertensive efficacy of telmisartan treatment with or without active promotion of lifestyle changes in hypertensive patients at high cardiovascular risk
Study Design:
6,834 studies on the registry are indexed under Hypertension; 971 are open to participants now.
This study's enrollment of 5,827 is above the median of 210 across 1,392 observational studies indexed under Hypertension.
Browse Hypertension studies →Boehringer Ingelheim is the lead sponsor of 2,297 studies on the registry; 56 are open to participants now.
Of its 166 completed or terminated interventional studies of FDA-regulated products, 121 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
hypertensive patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
patients with essential hypertension aged >/= 18 years with one of the following risk factors: history of coronary artery disease or stroke/TIA or peripheral artery disease or diabetes mellitus.
Exclusion Criteria:
according to SPC
Blood pressure reduction
Time frame: 4 month
Change in metabolic parameters Safety
Showing the first 100 of 2,389 sites.
The record gives a start of Jan 2007 and a primary completion of Nov 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.